Novel agents for advanced pancreatic cancer

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinleye, Akintunde, Iragavarapu, Chaitanya, Furqan, Muhammad, Cang, Shundong, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741843/
https://www.ncbi.nlm.nih.gov/pubmed/26369833
_version_ 1782414082820800512
author Akinleye, Akintunde
Iragavarapu, Chaitanya
Furqan, Muhammad
Cang, Shundong
Liu, Delong
author_facet Akinleye, Akintunde
Iragavarapu, Chaitanya
Furqan, Muhammad
Cang, Shundong
Liu, Delong
author_sort Akinleye, Akintunde
collection PubMed
description Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.
format Online
Article
Text
id pubmed-4741843
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47418432016-03-23 Novel agents for advanced pancreatic cancer Akinleye, Akintunde Iragavarapu, Chaitanya Furqan, Muhammad Cang, Shundong Liu, Delong Oncotarget Review Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer. Impact Journals LLC 2015-06-03 /pmc/articles/PMC4741843/ /pubmed/26369833 Text en Copyright: © 2015 Akinleye et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Akinleye, Akintunde
Iragavarapu, Chaitanya
Furqan, Muhammad
Cang, Shundong
Liu, Delong
Novel agents for advanced pancreatic cancer
title Novel agents for advanced pancreatic cancer
title_full Novel agents for advanced pancreatic cancer
title_fullStr Novel agents for advanced pancreatic cancer
title_full_unstemmed Novel agents for advanced pancreatic cancer
title_short Novel agents for advanced pancreatic cancer
title_sort novel agents for advanced pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741843/
https://www.ncbi.nlm.nih.gov/pubmed/26369833
work_keys_str_mv AT akinleyeakintunde novelagentsforadvancedpancreaticcancer
AT iragavarapuchaitanya novelagentsforadvancedpancreaticcancer
AT furqanmuhammad novelagentsforadvancedpancreaticcancer
AT cangshundong novelagentsforadvancedpancreaticcancer
AT liudelong novelagentsforadvancedpancreaticcancer

Ejemplares similares